Human MAGEA3 adenoviral particles

The MAGEA3 (Melanoma-Associated Antigen A3) gene belongs to the MAGE family, a class of cancer-testis antigens (CTAs) that are primarily expressed in germ cells and various malignancies, but are largely silent in normal somatic tissues. MAGEA3 plays a crucial role in tumorigenesis and is frequently overexpressed in cancers such as melanoma, lung cancer, and hepatocellular carcinoma, making it a promising target for immunotherapy. Its immunogenicity enables it to elicit a robust T-cell response, which can be used for therapeutic purposes. MAGEA3 has been extensively studied as a biomarker and candidate for cancer vaccines, adoptive T-cell therapy, and gene therapy.

Human MAGEA3 adenoviral particles are recombinant adenoviral vectors designed to deliver the MAGEA3 gene to target cells, thereby achieving expression of the MAGEA3 antigen. These particles are constructed with a non-replicating adenoviral backbone to ensure safety while maintaining high transduction efficiency in a variety of cell types, including dendritic cells (DCs) and tumor cells. After infection, the adenoviral vector introduces the MAGEA3 gene into the host cell genome, resulting in the production of MAGEA3 protein. Human MAGEA3 adenoviral particles are widely used in preclinical and clinical studies to develop cancer vaccines and immunotherapies. They are able to induce potent and specific immune responses against tumors expressing MAGEA3, making them a valuable tool in oncology research.